![]() |
市場調查報告書
商品編碼
1778880
良性前列腺增生治療市場-全球產業規模、佔有率、趨勢、機會和預測,按藥物治療、手術治療、最終用戶、地區和競爭細分,2020 年至 2030 年Benign Prostate Hyperplasia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Treatment, By Surgical Treatment, By End User, By Region & Competition, 2020-2030F |
2024 年全球良性前列腺增生 (BPH) 治療市場價值為 15.3 億美元,預計到 2030 年將達到 25.1 億美元,預測期內的複合年成長率為 8.75%。全球良性前列腺增生 (BPH) 治療市場正在穩步成長,這得益於老齡化人口日益增多和泌尿健康意識不斷提高。 BPH 是一種非癌性攝護腺增大,會導致不適的泌尿症狀並嚴重影響生活品質。因此,對有效治療方案的需求——從藥物到微創手術和手術——正在各個地區不斷擴大。根據世界衛生組織 (WHO) 的預測,到 2050 年,大約 80% 的老年人口將生活在中低收入國家。此外,預計 2020 年至 2050 年間 80 歲及以上人口的數量將增加兩倍,達到近 4.26 億。年齡是良性前列腺增生 (BPH) 的主要風險因素,其在老年男性中的盛行率顯著上升。因此,全球老年人口的成長很可能在未來幾年推動 BPH 治療市場的大幅擴張,對有效診斷和管理解決方案的需求也將隨之增加。
市場概覽 | |
---|---|
預測期 | 2026-2030 |
2024年市場規模 | 15.3億美元 |
2030年市場規模 | 25.1億美元 |
2025-2030 年複合年成長率 | 8.75% |
成長最快的領域 | 阿爾法阻斷劑 |
最大的市場 | 北美洲 |
醫療技術的進步帶來了創傷更小、恢復時間更短、療效更佳的治療方法,鼓勵更多患者及時尋求介入。醫藥領域仍然是市場的重要組成部分,其中α受體阻斷劑和5-α還原酶抑制劑是常用的處方藥。同時,雷射療法和其他能量療法的興起,透過提供更安全、副作用更少的替代方案,正在重塑外科手術格局。新興經濟體醫療基礎設施的不斷改進也促進了診斷和治療的可近性,進一步推動了市場成長。生活方式的改變、醫療支出的增加以及泌尿外科領域的持續研發,正在推動良性前列腺增生(BPH)治療的變革。全球良性前列腺增生(BPH)治療市場著重於改善患者的舒適度和長期療效,隨著認知度的提升和技術創新的不斷進步,市場規模有望持續擴張。
人口老化
先進治療的成本高昂
轉向微創手術
Global Benign Prostate Hyperplasia (BPH) Treatment Market was valued at USD 1.53 billion in 2024 and is expected to reach USD 2.51 billion by 2030 with a CAGR of 8.75% during the forecast period. The global benign prostate hyperplasia (BPH) treatment market is experiencing steady growth, driven by the increasing prevalence of aging populations and rising awareness of urological health. BPH, a non-cancerous enlargement of the prostate gland, leads to uncomfortable urinary symptoms and significantly impacts quality of life. As a result, demand for effective treatment options-ranging from medication to minimally invasive procedures and surgery-is expanding across regions. According to World Health Organization (WHO) projections, by 2050, approximately 80% of the elderly population will live in low- and middle-income countries. Additionally, the number of individuals aged 80 and above is expected to triple between 2020 and 2050, reaching nearly 426 million. Age is the leading risk factor for benign prostatic hyperplasia (BPH), with its prevalence increasing significantly in older men. As a result, the growing global geriatric population is likely to drive substantial expansion in the BPH treatment market in the coming years, with heightened demand for effective diagnosis and management solutions.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 1.53 Billion |
Market Size 2030 | USD 2.51 Billion |
CAGR 2025-2030 | 8.75% |
Fastest Growing Segment | Alpha Blockers |
Largest Market | North America |
Advancements in medical technology have introduced less invasive treatment methods with shorter recovery times and improved outcomes, encouraging more patients to seek timely intervention. The pharmaceutical segment remains a key part of the market, with alpha-blockers and 5-alpha-reductase inhibitors being commonly prescribed. Meanwhile, the rise of laser therapies and other energy-based treatments is reshaping the surgical landscape by offering safer alternatives with reduced side effects. Growing healthcare infrastructure in emerging economies is also fostering access to diagnosis and treatment, further propelling market growth. The lifestyle changes, increased healthcare expenditure, and ongoing research and development in urology are contributing to the evolution of BPH management. With a focus on improving patient comfort and long-term results, the global BPH treatment market is poised to continue expanding as both awareness and technological innovation advance.
Key Market Drivers
Aging Population
The aging population is one of the most significant and influential drivers of the global benign prostate hyperplasia (BPH) treatment market. For instance, according to WHO 2025, global life expectancy at birth reached 73.3 years in 2024, rising by 8.4 years since 1995. The population aged 60 and older is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, with the trend accelerating notably in developing regions. As men age, the likelihood of developing BPH increases substantially, making age a primary risk factor for the condition. BPH is characterized by the non-cancerous enlargement of the prostate gland, which commonly affects men over the age of 50. This physiological change occurs due to hormonal fluctuations, particularly the imbalance between testosterone and dihydrotestosterone (DHT), which promotes prostate cell growth. Over time, this leads to the gradual thickening and growth of the prostate, often resulting in urinary symptoms such as increased frequency, urgency, and incomplete bladder emptying.
Globally, improvements in healthcare, nutrition, and living standards have significantly extended life expectancy. This demographic shift means a larger proportion of the population is entering age brackets where BPH is more prevalent. Consequently, the demand for diagnostic, pharmaceutical, and surgical interventions is increasing. Healthcare systems, especially in developed countries, are seeing a growing burden of age-related conditions, with BPH being a leading urological issue among elderly men.
As people live longer and prioritize quality of life in older age, there is greater willingness to seek treatment for chronic but manageable conditions like BPH. The aging population is also more likely to be covered by healthcare insurance or public health systems, which further facilitates access to treatment. In emerging economies, increasing awareness among the elderly and improvements in medical infrastructure are similarly boosting diagnosis and treatment rates.
As this demographic trend continues, it is expected that the prevalence of BPH will rise, placing sustained demand on healthcare providers and driving innovation in less invasive, more effective treatment solutions. In this context, the aging population not only fuels market growth but also shapes the evolution of therapeutic strategies and healthcare delivery models for BPH.
Key Market Challenges
High Cost of Advanced Treatments
The high cost of advanced treatments poses a significant challenge to the growth and accessibility of the global benign prostate hyperplasia (BPH) treatment market. As medical technology evolves, newer treatment modalities such as laser therapies (e.g., HoLEP, GreenLight), water vapor therapy (Rezum), and prostatic urethral lift (UroLift) have emerged as preferred options due to their minimally invasive nature, shorter recovery times, and reduced side effects. However, these benefits come at a considerable financial cost. The equipment required for these procedures is often expensive, and so are the associated operational and maintenance costs, which are ultimately passed on to the patients or healthcare systems.
In many countries, especially those with limited healthcare funding or weak insurance infrastructure, the affordability of such advanced treatments becomes a major barrier. Patients in low- and middle-income regions may be forced to rely on older, more invasive procedures or pharmacological therapies, even when newer options would offer better outcomes. The private healthcare settings tend to dominate the availability of these innovations, making them inaccessible to individuals relying on public health services.
This economic disparity not only limits patient access but also discourages widespread adoption by healthcare providers due to the high initial investment. In addition, inconsistent or inadequate reimbursement policies in many regions further restrict the uptake of newer treatment modalities, particularly in outpatient settings. Without broader financial support or cost reduction strategies, the high cost of advanced BPH treatments remains a key obstacle to ensuring equitable access and scaling the market globally.
Key Market Trends
Shift Toward Minimally Invasive Procedure
The shift toward minimally invasive procedures is one of the most prominent trends shaping the global benign prostate hyperplasia (BPH) treatment market. Traditionally, BPH treatment involved surgical interventions such as transurethral resection of the prostate (TURP), which, while effective, often required prolonged hospital stays, significant recovery time, and a higher risk of complications such as bleeding and sexual dysfunction. In contrast, minimally invasive procedures offer a less traumatic alternative with quicker recovery, fewer complications, and a reduced risk of side effects, making them increasingly popular among both patients and healthcare providers.
Technologies like laser therapy (e.g., Holmium Laser Enucleation of the Prostate, HoLEP), prostatic urethral lift (UroLift), and water vapor therapy (Rezum) have gained traction due to their ability to treat BPH with precision and efficiency. These treatments are performed using advanced instruments that can target the enlarged prostate tissue without the need for large incisions, leading to shorter hospital stays, faster recovery times, and less post-operative pain. As a result, many patients are opting for these procedures over traditional surgery, valuing the minimal downtime and reduced risks.
This shift also aligns with a broader trend in healthcare toward procedures that maximize patient comfort and minimize disruption to daily life. The growing popularity of minimally invasive treatments is driving innovation in the field, encouraging the development of more effective, less invasive therapies. As awareness of these alternatives spreads, the market for minimally invasive BPH treatments is expected to expand, offering more choices for patients and enhancing the overall treatment landscape.
In this report, the Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostate Hyperplasia (BPH) Treatment Market.
Global Benign Prostate Hyperplasia (BPH) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report: